Literature DB >> 14566323

Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts.

Wenyi Wei1, Utz Herbig, Shan Wei, Annie Dutriaux, John M Sedivy.   

Abstract

Current models envision replicative senescence to be under dual control by the p53 and retinoblastoma (RB) tumour-suppressor pathways. The role of the p16(INK4a)-RB pathway is controversial, and the function of RB in human cells has not been tested directly. We used targeted homologous recombination to knock out one copy of RB in presenescent human fibroblasts. During entry into senescence, RB+/- cells underwent spontaneous loss of heterozygosity and the resultant RB-/- clones bypassed senescence. The extended lifespan phase was eventually terminated by a crisis-like state. The same phenotype was documented for p21(CIP1/WAF1) and p53 heterozygous cells, indicating that loss of function of all three genes results in failure to establish senescence. By contrast, the abolition of p16 function by the expression of a p16-insensitive cyclin-dependent kinase 4 protein or siRNA-mediated knockdown provided only minimal lifespan extension that was terminated by senescence. We propose that p53, p21 and RB act in a linear genetic pathway to regulate cell entry into replicative senescence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566323      PMCID: PMC1326371          DOI: 10.1038/sj.embor.embor7400001

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  25 in total

1.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.

Authors:  J Sage; G J Mulligan; L D Attardi; A Miller; S Chen; B Williams; E Theodorou; T Jacks
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

Review 2.  Gene targeting and somatic cell genetics--a rebirth or a coming of age?

Authors:  J M Sedivy; A Dutriaux
Journal:  Trends Genet       Date:  1999-03       Impact factor: 11.639

Review 3.  Immortalisation and transformation revisited.

Authors:  Sarah Drayton; Gordon Peters
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

4.  Role of p14(ARF) in replicative and induced senescence of human fibroblasts.

Authors:  W Wei; R M Hemmer; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

5.  Oxidative stress shortens telomeres.

Authors:  Thomas von Zglinicki
Journal:  Trends Biochem Sci       Date:  2002-07       Impact factor: 13.807

Review 6.  Historical claims and current interpretations of replicative aging.

Authors:  Woodring E Wright; Jerry W Shay
Journal:  Nat Biotechnol       Date:  2002-07       Impact factor: 54.908

7.  Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures.

Authors:  W Wei; J M Sedivy
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

8.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

9.  Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function.

Authors:  Mark Morris; Peter Hepburn; David Wynford-Thomas
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

10.  INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.

Authors:  Sharon Brookes; Janice Rowe; Margarida Ruas; Susana Llanos; Paula A Clark; Martine Lomax; Marion C James; Radost Vatcheva; Stewart Bates; Karen H Vousden; David Parry; Nelleke Gruis; Nico Smit; Wilma Bergman; Gordon Peters
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

View more
  27 in total

Review 1.  When cells get stressed: an integrative view of cellular senescence.

Authors:  Ittai Ben-Porath; Robert A Weinberg
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 2.  Senescence from G2 arrest, revisited.

Authors:  Véronique Gire; Vjekoslav Dulic
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Cellular senescence and cancer chemotherapy resistance.

Authors:  Ryan R Gordon; Peter S Nelson
Journal:  Drug Resist Updat       Date:  2012-02-23       Impact factor: 18.500

4.  Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

Review 5.  What has senescence got to do with cancer?

Authors:  Goberdhan P Dimri
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

6.  CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation.

Authors:  David M Burns; Joel D Richter
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

7.  Purinergic P2Y₁₄ receptor modulates stress-induced hematopoietic stem/progenitor cell senescence.

Authors:  Joonseok Cho; Rushdia Yusuf; Sungho Kook; Eyal Attar; Dongjun Lee; Baehang Park; Tao Cheng; David T Scadden; Byeong Chel Lee
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

8.  Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a).

Authors:  Isil Guney; Shirley Wu; John M Sedivy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

9.  Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells.

Authors:  Amber Wilson; Lina A Shehadeh; Hong Yu; Keith A Webster
Journal:  BMC Genomics       Date:  2010-04-07       Impact factor: 3.969

10.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.